Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 33
1993 10
1994 21
1995 25
1996 35
1997 48
1998 52
1999 90
2000 95
2001 116
2002 133
2003 153
2004 141
2005 165
2006 175
2007 147
2008 148
2009 149
2010 149
2011 144
2012 164
2013 194
2014 202
2015 247
2016 235
2017 231
2018 221
2019 115
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

3,282 results
Results by year
Filters applied: . Clear all
Page 1
Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk?
Bidell MR and Lodise TP. Pharmacotherapy 2016 - Review. PMID 27138564
Risk with ofloxacin and levofloxacin appears to be exposure dependent, with higher doses and longer durations being most commonly associated with tendinopathy. ...Given widespread use of levofloxacin across patient care settings, knowledge of both patient- and drug-specific characteristics associated with increased risk of tendinitis and tendon rupture can promote safe use of levofloxacin and other fluoroquinolones....
Risk with ofloxacin and levofloxacin appears to be exposure dependent, with higher doses and longer durations being most commonly ass …
Levofloxacin-Induced Hyperpigmentation.
Castellanos-González M, et al. Actas Dermosifiliogr 2019. PMID 31133294
Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
Izadi M, et al. Recent Pat Antiinfect Drug Discov 2018 - Clinical Trial. PMID 30360748
Although standard regimen group (n=27, 36%) showed more consolidation than patients in Levofloxacin group (n=22, 29.3%), and the ground glass pattern was observed more in Levofloxacin group. CONCLUSION: We concluded that monotherapy with oral Levofloxacin was as effective as treatment with Ceftriaxone plus Azithromycin combination in patients with CAP who required hospitalization....
Although standard regimen group (n=27, 36%) showed more consolidation than patients in Levofloxacin group (n=22, 29.3%), and the grou …
Levofloxacin versus azithromycin for treating legionella pneumonia: a propensity score analysis.
Garcia-Vidal C, et al. Clin Microbiol Infect 2017 - Clinical Trial. PMID 28267637 Free article.
OBJECTIVES: Concerns have arisen regarding the equivalence of levofloxacin and some macrolides for treating community-acquired legionella pneumonia (LP). ...RESULTS: We documented 446 patients with LP, of which 175 were treated with levofloxacin, 177 with azithromycin and 58 with clarithromycin. ...
OBJECTIVES: Concerns have arisen regarding the equivalence of levofloxacin and some macrolides for treating community-acquired legion …
A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.
Connolly LE, et al. Antimicrob Agents Chemother 2018 - Clinical Trial. PMID 29378708 Free PMC article.
Patients were randomized 1:1:1 to receive intravenous plazomicin (10 or 15 mg/kg of body weight) or intravenous levofloxacin (750 mg) once daily for 5 days. ...In the groups receiving plazomicin at 10 mg/kg, plazomicin at 15 mg/kg, and levofloxacin, microbiological eradication rates were, respectively, 50.0% (6 patients with microbiological eradication at TOC/12 patients treated [95% confidence interval {CI}, 21.1 to 78.9%]), 60.8% (31/51 [95% CI, 46.1 to 74.2%]), and 58.6% (17/29 [95% CI, 38.9 to 76.5%]) in the MITT population and 85.7% (6/7 [95% CI, 42.1 to 99.6%]), 88.6% (31/35 [95% CI, 73.3 to 96.8%]), and 81.0% (17/21 [95% CI, 58.1 to 94.6%]) in the ME population. ...
Patients were randomized 1:1:1 to receive intravenous plazomicin (10 or 15 mg/kg of body weight) or intravenous levofloxacin (750 mg) …
Population Pharmacokinetics and Pharmacodynamics Modeling of Oral Levofloxacin.
Jaruratanasirikul S, et al. J Med Assoc Thai 2018. PMID 29947489
The predicted CFRs for a target AUC0-24 /MIC ratio of 30 for S. aureus and S. pneumoniae were 83.12% and 92.63%, respectively for 500 mg levofloxacin, and 84.96% and 98.17%, respectively for 750 mg levofloxacin. The predicted CFRs for a target AUC0-24 /MIC ratio of 125 for E. coli and Klebsiella spp. were 84.25% and 88.81%, respectively for 500 mg levofloxacin and 86.00% and 91.34%, respectively for 750 mg levofloxacin. ...
The predicted CFRs for a target AUC0-24 /MIC ratio of 30 for S. aureus and S. pneumoniae were 83.12% and 92.63%, respectively for 500 mg …
Levofloxacin-induced rhabdomyolysis: a case report.
John F, et al. J Med Case Rep 2016. PMID 27557756 Free PMC article.
There are scarce reports in the literature associating rhabdomyolysis to levofloxacin. We describe a case of levofloxacin-induced rhabdomyolysis. ...His symptoms resolved after discontinuation of levofloxacin and supportive care. CONCLUSIONS: It is fascinating that our patient has a prior history of rhabdomyolysis, likely from levofloxacin. ...
There are scarce reports in the literature associating rhabdomyolysis to levofloxacin. We describe a case of levofloxacin-indu …
Cardiac risks associated with antibiotics: azithromycin and levofloxacin.
Lu ZK, et al. Expert Opin Drug Saf 2015 - Review. PMID 25494485 Free PMC article.
INTRODUCTION: Azithromycin and levofloxacin have been shown to be efficacious in treating infections. The adverse drug events associated with azithromycin and levofloxacin were considered rare. ...This study should not preclude clinicians from avoiding azithromycin and levofloxacin. If a patient has an indication to receive an antibiotic and if azithromycin or levofloxacin is needed, it may be used, but the potential risks must be understood....
INTRODUCTION: Azithromycin and levofloxacin have been shown to be efficacious in treating infections. The adverse drug events associa …
Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).
Seddon JA, et al. Trials 2018 - Clinical Trial. PMID 30572905 Free PMC article.
METHODS: The tuberculosis child multidrug-resistant preventive therapy (TB-CHAMP) trial is a phase III cluster randomised placebo-controlled trial to assess the efficacy of levofloxacin in young child contacts of MDR-TB cases. ...Eligible children are randomised by household to receive daily levofloxacin (15-20 mg/kg) or matching placebo for six months. ...
METHODS: The tuberculosis child multidrug-resistant preventive therapy (TB-CHAMP) trial is a phase III cluster randomised placebo-controlled …
Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
Deshpande D, et al. Clin Infect Dis 2018. PMID 30496461 Free PMC article.
BACKGROUND: Levofloxacin is used for the treatment of multidrug-resistant tuberculosis; however the optimal dose is unknown. ...AI algorithms identified an AUC0-24/MIC of 160 as predictive of microbiologic cure, followed by levofloxacin 2-hour peak concentration and body weight. ...
BACKGROUND: Levofloxacin is used for the treatment of multidrug-resistant tuberculosis; however the optimal dose is unknown. ...AI al …
3,282 results
Jump to page
Feedback